Circassia Pharmaceuticals plc announced a number of changes to its Board and Executive Management. Circassia announced that its Chief Executive Officer and Co-Founder, Steve Harris, has informed the Company of his intention to retire following 13 years leading the business and will step down from the Board as an Executive Director on 31 December 2019. Steve will work during the first months of 2020 to ensure a smooth transition of leadership. Circassia also announced with immediate effect the appointment of highly experienced life science company Director Ian Johnson as the Company's Executive Chairman. Ian is currently Non-Executive Chairman of Redcentric PLC and a Non-Executive Director of Ergomed PLC. He was previously Executive Chairman of Bioquell PLC and Non-Executive Chairman of Quantum Pharma PLC, Cyprotex PLC and Celsis Group Ltd, following a number of years as CEO of Biotrace International PLC. Ian's appointment follows a search to replace Circassia's outgoing Chairman, Dr. Francesco Granata, who, as announced in the Company's preliminary financial results on 1 May 2019, previously informed the Company of his intention to retire after six years in the role. In addition to the changes above, Garry Watts, an experienced Chairman and Non-Executive Director with extensive healthcare experience has agreed to join Circassia's Board on 2 March 2020 as an additional Non-Executive Director and Senior Independent Director. Garry is Non-Executive Chairman of Spire Healthcare Group PLC and until early 2020 of Foxtons Group PLC; he was Non-Executive Chairman at BTG plc until its sale to Boston Scientific earlier this year.